Most nonclinical safety studies performed to satisfy regulatory requirements include numerous anatomic and clinical pathology endpoints. Consequently, the traditional predominant role of the pathologist in the pharmaceutical industry has focused upon the interpretation of histologic changes in tissues and of clinicopathologic changes in blood from animals that had been exposed to new chemical entities. In addition to this conventional role, pathologists are increasingly being recognized for their expanded contributions to drug discovery and development.
ROLE OF THE PATHOLOGIST IN THE PHARMACEUTICAL INDUSTRY
Most nonclinical safety studies performed to satisfy regulatory requirements include numerous anatomic and clinical pathology endpoints. Consequently, the traditional predominant role of the pathologist in the pharmaceutical industry has focused upon the interpretation of histologic changes in tissues and of clinicopathologic changes in blood from animals that had been exposed to new chemical entities. In addition to this conventional role, pathologists are increasingly being recognized for their expanded contributions to drug discovery and development.
The medical training, specialty or residency training, and comparative medicine perspective place the industrial pathologist in a unique position to contribute broadly to the objectives of drug discovery and development programs. In addition, the technologies in the pathologist's repertoire have broad application and utility to many areas of biomedical research in the pharmaceutical industry. Such objectives and areas of research include characterization of ! disease states; identification of modified disease states as a response to administration of potential therapies; characterization and quantification of toxic responses to drug administration ; delineation of mechanisms of toxicities and potential relevance to target species; and facilitation of multidisciplinary efforts to monitor for the clinical occurrence, progression, and reversibility of adverse events.
The business and science of pharmaceutical research and development is increasingly complex, and the pressures associated with them create competitive advantages for companies that are able to deploy resources in novel and beneficial ways. Use of pathologists to support drug discovery represents one such approach.
SELECTED EXAMPLES OF SIGNIFICANT IMPACT OF DISCOVERY PATHOLOGY AT PFIZER

Characterization of Disease States and Modifications in
Response to Therapies Animal models of disease are an indispensable part of the drug-and biological product-discovery process. For human health products, animal models provide a relatively inexpensive efficacy and potential safety readout at a very early point in the discovery process, before significant resources have been allocated. For animal health products, such models may be developed within the eventual target species and can provide more than just an early screening mechanism. Pathologists perform a critical role in deter-mining whether such models are sufficiently similar to the natural disease to allow crucial decisions to be made about development options pertaining to drugs or biologics tested in the model. In addition, once such a model has been accepted, the pathologist may be able to work with the discovery teams to validate more efficient means of screening. For example, it may be advantageous to know whether bacteria have been eliminated from tissues during a trial with a putative antibiotic. Culture may not be useful, as the antibiotic may prevent growth but not kill the organism. Pathologists evaluating the disease process can record the presence of bacteria within sections, and molecular biologists can utilize polymerase chain reaction (PCR) analysis for bacteria using large pieces of tissue. Sensible statistical analysis and good teamwork may yield the optimum-sized block of tissue upon which to perform PCR in order to achieve a result equivalent to histopathology, or, alternatively, the comparison can yield the appropriate number of sections to histologically examine in order to equal the PCR results.
Validation of tumor-bearing animal models for use in studies to investigate efficacy of new noncytotoxic agents now requires demonstration of in situ target expression or overexpression by the model tumor cells. Immunohistochemistry and in situ hybridization are sensitive and specific methods for morphologically validating these animal models. Additionally, histopathology, immunohistochemistry, and in situ hybridization are useful for monitoring anticancer treatment effects in tumor models. Histologic correlates for induced changes in tumor weight or size can be important for determining the true potency of a compound: for example, by demonstrating tumor-cell eradication within the residual stroma of a treated mass. Immunohistochemistry and in situ hybridization can also confirm a compound's mechanism of action in vivo by demonstrating changes in the expression of a therapeutic target by tumor cells following drug treatment. Some of these assays developed in animal models for the demonstration of biochemical endpoints in situ can subsequently be translated into corresponding assays for clinical use in order to provide proof-of-concept for a novel therapeutic approach.
Animal models for vaccine development require a number of endpoints for validation. Included among these are antibody levels, cellular immunity measurements in vitro and in vivo, and clinical, physiological, and morphological correlates for disease progression and amelioration. Gross and microscopic examination of target tissues with cutting-edge technologies, such as immunohistochemistry, immunoelectron microscopy, confocal microscopy, and in situ hybridization, allow the pathologist to interact with the discovery biologists to form a team that can quickly target problem areas. In most cases, morphological description of the severity and extent of the disease process is a key element in the assessment of a vaccination-challenge experiment. In addition, the presence, or hopefully absence, of the etiological agent in tissue sections provides researchers (early in the discovery process) and regulators (in filing dossiers) with further evidence of a vaccine's efficacy. Close interaction of biologists and pathologists who develop a range of vaccines in a variety of species has yielded a fruitful synergistic relationship, in which pathologists have a pivotal role in furthering the understanding of disease target and pathogenesis. This understanding allows teams to more rapidly reach decision points for candidate progression. Alternatively, timely termination of a project allows resources to be allocated in the most efficient manner.
Genetically altered mice are being used increasingly in drug discovery, and the application of pathology techniques to these models is a natural fit. The approach is to first sample &dquo;target&dquo; organs to determine whether the intended lesions are produced. Often, molecular biological and biochemical data are generated in parallel with histology data, and results are compared among collaborators from the disciplines. Lines of mice that clear the first hurdle are evaluated extensively for blood (clinical pathology) or tissue (histology of many organs) alterations that could systemically modulate the biology of the target tissue or organ. The necessity for pathology support for these models is increasingly being recognized within both industry and academia.
In vitro models and screens are the lifeblood of the discovery research supported by chemistry programs. Because these screens generate data on very specific physiologic or biochemical endpoints, investigators periodically seek to corroborate their data with histologic evaluation. Whether they are using routine hematoxylin and eosin histology to study neuronal survivability in hippocampal slice cultures or using image analysis to quantify neuronal growth in dorsal root-ganglion cultures, taking time to produce the morphologic data is an insurance premium that many investigators are eager to pay. In many cases, the morphologic data corroborate the physiologic data, but occasionally it is discovered that the physiologic data are misleading, and new approaches are needed.
Characterization and Quantification of Toxic Responses to Drug Administration
Rodents used for efficacy or early tolerance testing of novel compounds are routinely sacrificed at study end, usually so that the researchers can obtain blood for pharmacokinetic analyses. Discovery scientists are now learning that they can increase the useful information obtained from these studies, with little additional effort, by sampling major and grossly abnormal organs for submission to the histopathology laboratory. Side effects identified histologically can help to differentiate related novel compounds, guide structure activity relationship (SAR) refinements prior to nomination of a compound for development, or focus observation in early toxicology studies. Special care should be taken to appreciate species and strain differences in terms of morphology and pathophysiological responses and to avoid overinterpreting tissue changes in these very early studies. Still, satisfying limited safety criteria in efficacy studies can only increase the probability of candidate success in preclinical toxicology testing, thereby decreasing the safety-related attrition of compounds in development. Delineation of Mechanisms of Toxicities and Potential Relevance to Species of Choice In cases in which the nature of toxicity identified in nonclinical safety testing impedes clinical progress, delineation of the responsible mechanism and of its relevance to humans can allow for restoration of a program. These efforts may be successful when the current state of knowledge (i.e., interpretive morphologic data) is applied most appropriately to the design of future studies. Fruitful brainstorming ideas, which arise through discussions with specialists from multiple disciplines (e.g., biochemistry, chemistry, the study of metabolism, molecular biology, and toxicology), can be &dquo;triaged&dquo; in order to prioritize resources that support scenarios that are consistent with known morphologic data. A significant contribution to this work will often occur in chemistry laboratories, where chemists synthesize structurally &dquo;new&dquo; compounds in order to avoid the toxicity.
Facilitation of Multidisciplinary Efforts to Monitor for the Clinical Occurrence, Progression, and Reversibility of Adverse Events
Critical data to address clinical safety implications can be obtained in a &dquo;reverse flow&dquo; scenario, in which toxicology groups collaborate with discovery biologists to perform testing in animal models that are &dquo;on line&dquo; in the biologist's laboratory. Such an example is published in this issue of Toxicologic Pathology (Burkhardt et al), in which the effects of a quinolone antibacterial on synovial-fluid composition were studied in a hamster model. This study showed that synovial fluid evaluation was not a good predictor of clinical toxicity in hamsters and, therefore, that this invasive test should be avoided in human pediatric studies.
SUMMARY
Pathologists are uniquely qualified to play a central role in driving drug discovery and development programs by (a) establishing disease models to assess potential therapies, (b) characterizing modifications in the disease state in response to therapies, (c) characterizing toxicologic responses to drug candidates, (d) facilitating elaboration of mechanisms of toxic responses and establishing relevance of toxic responses to species of choice, and (e) facilitating multidisciplinary efforts to monitor for the clinical occurrence, progression, and reversibility of adverse events. Overall, the unique biomedical training of the pathologist prepares him/her to assume a critical leadership role in pharmaceutical research and development problem solving. Application of new technologies, collaboration on the project team and at individual levels, and consistent high-level contribution will be needed if the pathologist is to successfully assume or attempt to become a leader in terms of these diverse responsibilities.
